Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
Therachon, achondroplasia therapy developer, closes $35M Series A
Therachon has raised significant funding to support clinical proof of its soluable form of human fibroblast growth factor receptor 3. This could treat achondroplasia, a genetic mutation that is the leading cause of dwarfism.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.